Clinical Trial Update: Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Rituximab plus Venetoclax as frontline therapy for marginal zone lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Gottfried von Keudell, MD PhD | Conditions: Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING